Pharmacyte Biotech Inc (OTCMKTS:PMCB) has had a good start this month, with steady trading and its share value rising to $0.151. Investors have seen the company move quickly from a dime to about $0.60 last year. Even though the share value was stable for quite a long time, its move has sparked the interest of investors who are looking for the history to repeat itself.
The company mainly works on the development of treatments for cancer and diabetes, two of the most feared yet common diseases. It has recently made a great breakthrough, with its “Cell in a Box”, cell encapsulation, technology. The company hopes to expand the use of this technology for the treatment of other lethal diseases as well. The company also has gained due to a recent report by Transparency Market Research, which put the global diabetes and cancer treatment market at $54.04 billion. This number is also expected to reach $83 billion by 2019.
With the company’s technology showing promise and truly displaying innovation, it is no surprise that the investors think that PMCB would take a large share of this amount. Additionally, the company has increased its chances of doing so, with a number of events it has planned out this year, each to start testing one of its new technologies. Additionally, the company is also planning to research on cannabinoids to help remove any side effects that may be left after the patient’s treatment with Cell in a Box.
The move could be seen as a sign that the company might be trying to break into the growing pot industry and develop new medicinal products. The company also acquired a number of big names in the areas of research sciences to assist the company on its projects. Right now, Pharmacyte Biotech Inc (OTCMKTS:PMCB) seems to be making all the right moves and fate seems to be helping it out. How far would this go? We will have to wait until the first trial to see.